Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Regenxbio (RGNX) Cost of Revenue (2016 - 2024)

Regenxbio has reported Cost of Revenue over the past 11 years, most recently at $6.3 million for Q4 2024.

  • Quarterly results put Cost of Revenue at $6.3 million for Q4 2024, down 43.78% from a year ago — trailing twelve months through Dec 2024 was $33.6 million (down 9.8% YoY), and the annual figure for FY2024 was $33.6 million, down 9.8%.
  • Cost of Revenue for Q4 2024 was $6.3 million at Regenxbio, down from $12.4 million in the prior quarter.
  • Over the last five years, Cost of Revenue for RGNX hit a ceiling of $23.1 million in Q4 2021 and a floor of $3.4 million in Q1 2020.
  • Median Cost of Revenue over the past 5 years was $10.9 million (2023), compared with a mean of $10.6 million.
  • Biggest five-year swings in Cost of Revenue: surged 11655.17% in 2020 and later tumbled 73.84% in 2023.
  • Regenxbio's Cost of Revenue stood at $10.3 million in 2020, then surged by 124.8% to $23.1 million in 2021, then tumbled by 44.56% to $12.8 million in 2022, then decreased by 12.09% to $11.2 million in 2023, then tumbled by 43.78% to $6.3 million in 2024.
  • The last three reported values for Cost of Revenue were $6.3 million (Q4 2024), $12.4 million (Q3 2024), and $10.6 million (Q2 2024) per Business Quant data.